Published in Brain Pathol on June 18, 2012
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol (2013) 1.15
To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol (2013) 1.04
Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 0.91
Adult pilocytic astrocytomas: clinical features and molecular analysis. Neuro Oncol (2014) 0.80
Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment. Front Oncol (2014) 0.79
Why does melanoma metastasize into the brain? Genes with pleiotropic effects might be the key. Front Genet (2013) 0.79
Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. J Cancer Res Clin Oncol (2015) 0.78
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol (2009) 6.43
Radiotherapy for glioblastoma in the elderly. N Engl J Med (2007) 5.64
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol (2009) 5.06
Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nat Genet (2010) 4.69
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain (2010) 3.53
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood (2012) 3.44
OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain (2007) 3.35
Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol (2010) 3.29
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol (2007) 3.23
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res (2010) 3.13
Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature (2009) 3.07
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res (2009) 2.95
Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis (2008) 2.70
Should preoperative chest CT be recommended to all colon cancer patients? Ann Surg (2014) 2.65
The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol (2012) 2.53
Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol (2006) 2.51
Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology (2009) 2.44
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (2004) 2.15
MicroRNA profiling in human medulloblastoma. Int J Cancer (2009) 2.12
Second-look surgery for ependymoma: the Italian experience. J Neurosurg Pediatr (2011) 2.12
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08
Coexistence between carotid artery stenosis and colorectal adenomatous polyps in middle-aged men. Digestion (2009) 2.02
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol (2012) 2.01
Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol (2009) 1.99
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol (2009) 1.99
Epidural neural fibrolipoma of the thoracic vertebral canal. J Neurosurg Spine (2012) 1.98
The tertiary structure and domain organization of coagulation factor VIII. Blood (2007) 1.96
Genome-wide association study of glioma and meta-analysis. Hum Genet (2012) 1.96
Leptomeningeal metastases from solid malignancy: a review. J Neurooncol (2005) 1.94
Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol (2006) 1.92
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood (2005) 1.86
Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain (2003) 1.85
Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol (2010) 1.82
Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol (2007) 1.76
Risk factors for immediate postpolypectomy bleeding of the colon: a multicenter study. Am J Gastroenterol (2006) 1.73
Ependymoma with neuropil-like islands: a case report with diagnostic and histogenetic implications. Acta Neuropathol (2004) 1.73
An extracellular matrix glues together the aerial-grown hyphae of Aspergillus fumigatus. Cell Microbiol (2007) 1.73
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer (2008) 1.72
Mutations in FAM111B cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis. Am J Hum Genet (2013) 1.70
Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology (2008) 1.68
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol (2009) 1.68
Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol (2013) 1.68
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol (2012) 1.68
Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer (2003) 1.67
Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. FEBS Lett (2005) 1.66
BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer (2008) 1.66
Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol (2004) 1.65
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol (2008) 1.65
Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis (2003) 1.64
REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci U S A (2004) 1.63
A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg (2003) 1.60
Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol (2004) 1.59
Genetic risk profiles identify different molecular etiologies for glioma. Clin Cancer Res (2010) 1.59
Pilocytic astrocytomas in children: prognostic factors--a retrospective study of 80 cases. Neurosurgery (2003) 1.58
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer (2004) 1.58
Dural metastases. J Neurooncol (2005) 1.56
ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. Cancer Cell Int (2010) 1.54
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res (2012) 1.54
Gender-related differences in visceral perception in health and irritable bowel syndrome. J Gastroenterol Hepatol (2006) 1.53
Molecular classification of low-grade diffuse gliomas. Am J Pathol (2010) 1.51
TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol (2013) 1.51
Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev (2007) 1.50
Frameless stereotactic cerebral biopsy: our experience in 296 cases. Stereotact Funct Neurosurg (2011) 1.49
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol (2010) 1.48
Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol (2007) 1.48
NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat (2010) 1.47
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab (2010) 1.46
Adrenomedullin as a therapeutic target in angiogenesis. Expert Opin Ther Targets (2010) 1.45
Pitfalls in the diagnosis of brain tumours. Lancet Neurol (2006) 1.45
Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol (2006) 1.43
Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri. Neurology (2003) 1.43
MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol (2007) 1.42
Filiform serrated adenoma is an unusual, less aggressive variant of traditional serrated adenoma. Pathology (2012) 1.42
Comparison of malignant potential between serrated adenomas and traditional adenomas. J Gastroenterol Hepatol (2007) 1.42
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol (2007) 1.42